Posted on

Ungerboeck’s Latest Acquisition Enables Launch of Risk Management Tool for Venues and Events

Ungerboeck's Latest Acquisition Enables Launch of Risk Management Tool for Venues and Events

ST. LOUIS, May 24, 2022 (GLOBE NEWSWIRE) — Ungerboeck, the global leader in event management software, announced today that it has acquired the products developed by risk management agency Reliance Risk and will be debuting an industry-first application for mitigating risk to events and venues.

Risk management is an essential part of venue management and event planning. As the industry continues to be impacted by major shocks like the COVID-19 pandemic, terrorism, accidents, and severe weather incidents, Ungerboeck is committed to helping its customers better manage risks of all kinds.

The acquisition of both Reliance Risk products, RiskSense101 and VRM360, gives Ungerboeck the power to offer a valuable new solution: Risk Manager by Ungerboeck. The new application is specifically designed to give venue and event organizers a better understanding of threats and help them be proactive instead of reactive in the face of potential issues. 

“The unique nature of events dictates the need for a customized, simple, but powerful technology solution to help mitigate and monitor risk,” said Wayne Middleton, founder of Risk Sense Technologies and co-developer of the new application. “We have built this into Risk Manager by Ungerboeck and are grateful for the shared vision, passion, and global reach that Ungerboeck brings to help our industry manage risk.”

Steve Mackenzie, Executive Vice President of Ungerboeck, said the new application fills a void in the market. 

“Over the past few years, several events have become major headlines for all the wrong reasons,” he said. “Think of the Manchester Arena bombing, the shooting in Las Vegas, or the Astroworld crowd incident. By offering this tool, we are ensuring venue and event operators are equipped to identify potential risks and produce the necessary tasks and reports to back up the process.” 

Before joining the Ungerboeck family, Middleton’s risk management software was already used in venues across the Asia Pacific Region. Now thanks to Ungerboeck’s global reach, thousands of additional organizations will benefit. 

“Qudos Bank Arena, along with the larger ASM Global operated venues throughout Australia, have held a license to the software for over seven years. It has been an important tool in helping us understand the risks that our venues encounter and ensure that we have taken appropriate measures to mitigate them,” said Steve Hevern CVE, General Manager of Qudos Band Arena. “We congratulate Wayne and Ungerboeck on this global partnership and look forward to more innovative technology that will help us continue to host safe and successful events.” 

Middleton will continue in his role as Managing Director of Reliance Risk, and as a risk management consultant, setting the benchmark for best practices across the industry.

“We’ll build on the unique system that Wayne, a world-renowned risk management expert, has developed over the past decade,” Mackenzie said. “This is incredibly exciting for the market to finally have access to a dedicated risk management software.” 

About Ungerboeck

Ungerboeck provides industry-leading event and venue management software to over 50,000 users in more than 50 countries, empowering the people that bring people together. Its comprehensive platform offers event professionals powerful Software as a Service (SaaS) technology that provides a 360-view of their business, allowing them to cut costs, save time, and increase revenue. Founded in 1985, Ungerboeck is headquartered in the United States, with regional presence in Germany, France, Mexico, England, Australia, Mainland China, Hong Kong, and Singapore. ungerboeck.com

About Reliance Risk

Reliance Risk is a risk management consultancy established to provide quality risk management and safety support. We offer services across the risk spectrum with expertise in health and safety, business risk, business continuity and resilience, security, and emergency management. Many of our consultants have international risk management experience working across a range of industry sectors and we draw upon our network of technical experts to provide the right solution for client needs.


        
Posted on

Clopidogrel monotherapy linked with reduced risk of net adverse clinical events, study finds

Clopidogrel monotherapy linked with reduced risk of net adverse clinical events, study finds

Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin monotherapy beyond 12 months after PCI in high-risk patients during the chronic maintenance period. This study found that clopidogrel monotherapy was associated with reduced risk of net adverse clinical events (NACE; all-cause death, MI, stent thrombosis, stroke, or BARC type 2, 3, or 5 bleeding) and MACCE (death, MI, stent thrombosis, stroke), and a numerical decrease in major or clinically relevant nonmajor bleeding (BARC type 2, 3, or 5 bleeding), compared with aspirin monotherapy. The findings were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions.

P2Y12 inhibitor monotherapy reduces bleeding risk without increasing the risk of ischemic events compared with dual antiplatelet therapy (DAPT), especially in the first 12 months following percutaneous coronary intervention (PCI). Recent research showed that among patients who were event free for six to 18 months post-PCI and successfully received the intended duration of DAPT, clopidogrel monotherapy was superior compared with aspirin monotherapy in terms of NACE. However, optimal antiplatelet monotherapy during the chronic maintenance period beyond 12 months after PCI with drug-eluting stents in high-risk patients in real-world settings is previously unknown.

In total, 8,377 consecutive patients at high risk for both bleeding and thrombosis were identified from the prospective Fuwai PCI Registry if they satisfied one clinical and one angiographic criterion. Patients who received antiplatelet (aspirin or clopidogrel) monotherapy longer than 12 months and were free from ischemic and bleeding events at 12-month post-PCI without extended duration of DAPT were included. The primary endpoint was net adverse clinical events (NACE) from 12 to 30 months. The key secondary endpoints were major adverse cardiac or cerebral events (MACCE) and major or clinically relevant nonmajor bleeding (BARC type 2, 3 or 5).

“These findings show for the first time clopidogrel monotherapy is associated with reduced risk of long-term NACE and MACCE,” said Hao-Yu Wang, Cardiometabolic Medicine Center, Coronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. “Our results may have important practical implications for determining the optimal treatment for patients requiring a single antiplatelet drug, either aspirin or clopidogrel, for secondary prevention of ischemic events in high-risk PCI population.”

Of 7,392 high-risk patients that were event-free after the first year and adherent to DAPT, 5,664 patients who received antiplatelet monotherapy (clopidogrel monotherapy: n=1,974 and aspirin monotherapy: n=3690) were included in the present analysis. Researchers found that between 12 and 30 months, the net adverse clinical events were lower with clopidogrel monotherapy compared to aspirin monotherapy (Kaplan-Meier estimate: 2.5% vs. 5.0%; adjusted HR:0.566, 95% CI: 0.403-0.795). Clopidogrel monotherapy was associated with lower risk for MACCE (Kaplan-Meier estimate: 1.0% vs. 3.1%, log-rank p = 0.001 ), as well as lower incidence rates of all-cause death, MI, and stroke. The difference in risk between the groups was statistically similar for major or clinically relevant nonmajor bleeding (Kaplan-Meier estimate: 1.5% vs. 2.1%, log-rank p = 0.199).

Researchers recommended that their findings should be further investigated through a randomized clinical trial.

Posted on

Erectile Dysfunction Ups Risk for Major Adverse Cardiovascular Events

Vascular system, illustration

Men with erectile dysfunction (ED) are at increased risk for major adverse cardiovascular events (MACE), especially those who live in rural areas, according to study findings presented at the 2022 American Urological Association annual meeting in New Orleans, Louisiana.

The study included 428,241 men, of whom 49,959 had ED (32,138 from urban areas and 17,821 from rural areas) and 378,282 did not (233,073 and 145,209 from urban and rural areas, respectively).

Overall, MACE occurred in 8.9% of men with ED compared with 4.6% of those without ED. The proportions of men who experienced MACE were 8.2% and 10.2% among men with ED from urban and rural areas, respectively, and 4.2% and 5.2%, respectively, for men without ED from urban and rural areas, respectively.


Continue Reading

Compared with men from urban areas who did not have ED, men with ED who lived in rural areas and those with ED from urban areas had a significant 54% and 26% higher risk for MACE, respectively, in weighted analyses, investigator Uday Mann, MD, of the University of Manitoba in Winnipeg, Canada, reported.

Among men with ED, those from rural areas had a significant 22% higher risk for MACE compared with those from an urban setting. Among men without ED, men from rural areas had a significant 14% increased risk for MACE compared with those from urban areas.

The median time to a MACE was 2721, 2620, 2520, and 2438 days in the ED urban, ED rural, no ED rural, and no ED urban groups, respectively.

The investigators adjusted for age, socioeconomic status, diabetes, hypertension, dyslipidemia, renal disease, and index year.

“It is imperative for health care professionals who manage patients with ED to discuss the risk of future cardiovascular disease and identify comorbid conditions to mitigate risk,” Dr Mann concluded.

The investigators considered men to have ED if they had at least 2 ED prescriptions (including oral, intraurethral, and/or injection therapies) filled within 1 year. They defined MACE as myocardial infarction, coronary revascularization procedures, ischemic stroke, or hospitalization for heart failure.

Reference

Mann U, Brar R, Patel P. Erectile dysfunction is an independent risk factor for major adverse cardiovascular events. Presented at AUA 2022, May 13-16, 2022, New Orleans, Louisiana. Abstract PD49-05.

Posted on

Fatigue in patients with advanced NASH may increase risk for adverse events

HGI0522Younossi_Graphic_01


Disclosures:
The study was funded by the Center for Outcomes Research in Liver Diseases and Gilead Sciences.


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Worse fatigue at baseline among patients with nonalcohol steatohepatitis-related advanced fibrosis and cirrhosis correlated with a higher risk adverse clinical events, according to published results.

“Although generally considered asymptomatic, almost half of patients with NASH have clinically significant fatigue which, in turn, has a profound negative impact on the overall patient experience,” Zobair M. Younossi, MD, president of Inova Medicine Services and professor and chairman of the department of medicine at Inova Fairfax Medical Campus in Virginia, and colleagues wrote in Clinical Gastroenterology and Hepatology. “In this context, ongoing clinical trials aim at finding a drug-based therapy for NASH that may reverse fibrosis and could also potentially improve fatigue. Given that, patient-reported outcome instruments are now commonly included in these trials in order to provide a comprehensive assessment of the impact of the investigational drugs on patients and their experience.”


HGI0522Younossi_Graphic_01



For 2 years, Younossi and colleagues followed 1,679 patients with biopsyconfirmed NASH, 802 had bridging fibrosis (F3) and 877 compensated cirrhosis (F4). Fatigue was quantified at baseline with the Chronic Liver Disease Questionnaire (CLDQ)- NASH fatigue domain. Time to liver-related clinical eventssuch as progression to histologic cirrhosis or hepatic decompensation in F3F4 was assessed with Cox proportional hazard model.

median follow-up of 16 months, 15% (n=123) of NASH F3 patients experienced liver-related events and 3.5% (n=31) of NASH F4 patients experienced hepatic decompensation. Among F3 patients, the mean baseline CLDQ-NASH fatigue score was 4.77hose who experienced liver-related events lower baseline scores 4.47 4.83. Among patients withF4, the mean fatigue score was 4.56 who decompensated3.74 4.59.

fter for confounders, correlation between lower fatigue scores and risk liver-related or decompensation events adjusted HR 0.85, per 1 point in fatigue score in F3; aHR = 0.62 in F4.

“This suggests that, in addition to commonly used clinical parameters, presence of clinically significant fatigue can identify NASH patients at risk for adverse events,” the authors wrote. “Since fatigue also negatively impacts patients [health-related quality of life] and work productivity, it adds to the disease burden related to NASH. Given the critical importance of fatigue in NASH, clinical trials of regimens for NASH should not only show improvement of surrogates of clinical endpoints, such as the stage of fibrosis or resolution of NASH, but also improvement in patient-reported endpoints, such as fatigue.”

 

Posted on

Genetic Mapping Predicts Risk of Cardiovascular Events in People With Type 2 Diabetes

CVD, cardiovascular, heart MRI, cardiac

Risk scores based on genetic mapping were found to correlate with hypertensive blood pressure (BP) traits and an increased likelihood of adverse cardiovascular events, such as stroke, myocardial infarction, and cardiovascular death, in individuals with type 2 diabetes (T2D), according to results of a study published in Hypertension. The risk of adverse cardiovascular events in those with higher genetic risk scores were unchanged by intensive glycemic therapy approaches.

Researchers conducted a post hoc analysis of the National Institutes of Health’s ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial (ClinicalTrials.gov Identifier: NCT00000620) to assess whether genetic variants influenced BP traits and adverse cardiovascular outcomes in individuals with T2D. Out of the 10,251 participants with T2D in the ACCORD trial, 6335 individuals had genetic data that were needed to calculate polygenic risk scores.

During the ACCORD trial, BP data were calculated using an average of 3 BP measurements with 5 minutes rest in between measurements. Overall, the median systolic blood pressure was 147 mm Hg, the median diastolic blood pressure was 83 mm Hg, and the median HbA1C was 8.1%.


Continue Reading

For the post hoc assessment, the researchers collected participant genotype data and compared these data with the Trans-OMICs Precision Medicine (TOPMed) Freeze 8 gene map, which consists of more than 1000 genetic variants known to affect blood pressure. The researchers calculated polygenic risk scores based on the number of matches between each participant’s DNA and the genetic variants known to influence BP. The greater the number of matches, the higher the risk score. The median polygenic risk score was 168.4 (range, 166.6-170.6).

After analyzing BP polygenic risk scores in relation to adverse cardiovascular outcomes, each degree of increase in the risk score was found to correlate with a 12% increased risk of cardiovascular events. Glycemic control therapy did not influence the BP polygenic risk scores, nor did it influence the primary outcome of cardiovascular risk prevention.

Study limitations included the pre-existing nature of the subset of participants available for analysis, as well as a lack of power to evaluate possible interactions due to the study’s post hoc design.

“These results invigorate the potential implications of [using] BP polygenic risk score in the primordial prevention of microvascular and macrovascular complications in T2D through early intensification of life-style measures such as healthy diet, exercise, smoking cessation, weight management, and BP control among those with high genetic risk,” the authors said.

This genetic risk assessment may especially benefit those with newly diagnosed T2D and those with prediabetes to encourage earlier adoption of a healthier lifestyle.

Reference

Parcha V, Pampana A, Bress AP, Irvin MR, Arora G, Arora P. Association of polygenic risk score with blood pressure and adverse cardiovascular outcomes in individuals with type II diabetes: insights from the ACCORD trial. Hypertension. Published online April 4, 2022. doi:10.1161/hypertensionaha.122.18976

Posted on

Risk for major adverse CV events elevated with type 2 diabetes, cognitive impairment

Hertzel C. Gerstein, MD, MSc

April 21, 2022

2 min read


Disclosures:
Gerstein reports receiving research grants from AstraZeneca, Eli Lilly, Merck, Novo Nordisk and Sanofi; receiving honoraria for speaking from Boehringer Ingelheim, DKSH, Eli Lilly, Novo Nordisk, Roche, Sanofi and Zuellig; and receiving consulting fees from Abbott, Covance, Eli Lilly, Hanmi, Kowa, Novo Nordisk, Pfizer and Sanofi. Please see the study for all other authors’ relevant financial disclosures.


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Adults with type 2 diabetes and cognitive impairment are more likely to experience major adverse cardiovascular events, stroke or CV mortality compared with those without cognitive impairment, according to study findings.

In an analysis of data from the REWIND trial, participants who scored 1.5 standard deviations below their country’s geometric mean on the Montreal Cognitive Assessment and the Digit Symbol Substitution Test were more likely to experience major adverse CV events, making cognitive impairment a potential predictor for CV health outcomes.


Hertzel C. Gerstein, MD, MSc

Gerstein is a professor and population health institute chair in diabetes research and care at McMaster University and Hamilton Health Sciences in Ontario, Canada.

“These findings highlight the relevance of cognitive function as an important risk factor for CV outcomes and suggest that patients with cognitive impairment should be offered proven cardioprotective therapies to mitigate their future risk of CV outcomes,” Hertzel C. Gerstein, MD, MSc, professor and population health institute chair in diabetes research and care at McMaster University and Hamilton Health Sciences in Ontario, Canada, told Healio.

Researchers collected data from 8,772 REWIND participants with type 2 diabetes who completed both the Montreal Cognitive Assessment and the Digit Symbol Substitution Test at baseline, 2 years, 5 years and their final trial visit. The Montreal Cognitive Assessment is a 30-item questionnaire assessing seven cognitive domains. The Digit Symbol Substitution Test presents nine symbols above blank squares, with a key corresponding each symbol to a number. Participants must place the correct number in each square in a spvan of 2 minutes. Scores on each test were standardized based on the participant’s country. Adults with a score 1.5 standard deviations below the mean score in their country were defined as having country-standardized substantive cognitive impairment. Those who had a mean score on both tests combined 1.5 standard deviations below their country’s mean were defined as having substantive cognitive impairment based on the geometric mean. Primary outcomes were incident major adverse CV events, incident stroke and CV mortality.

The findings were published in The Journal of Clinical Endocrinology & Metabolism.

Of the study cohort, 10.3% had substantive cognitive impairment and 6% had substantive cognitive impairment based on the geometric mean. Participants with substantive cognitive impairment did not have a significantly increased risk for major adverse CV events after adjusting for albuminuria, estimated glomerular filtration rate and retinopathy. However, in a fully adjusted model, those with substantive cognitive impairment based on the geometric mean had an increased risk for major adverse CV events compared with those without cognitive impairment (adjusted HR = 1.38; 95% CI, 1.09-1.77; P = .009).

Participants with substantive cognitive impairment (aHR = 1.35; 95% CI, 1.11-1.64; P = .002) and substantive cognitive impairment based on the geometric mean (aHR = 1.54; 95% CI, 1.22-1.93; P < .001) had an increased risk for either stroke or CV death compared with adults without cognitive impairment.

“These findings are consistent with other research suggesting that low cognitive scores on cognitive tests were a risk factor for a cardiovascular outcome,” Gerstein said. “This research extended those findings by using a composite measure of cognitive scores and prespecifying a threshold labeled substantive cognitive impairment. It also reported a novel way of combining the cognitive scores by calculating their geometric mean.”

For more information:

Hertzel C. Gerstein, MD, MSc, can be reached at gerstein@mcmaster.ca.

Posted on

ED Meds Linked to Higher Risk of Ocular Adverse Events

A photo of a man holding a Viagra pill and a glass of water.

Regular users of common medications for erectile dysfunction (ED) are at a higher risk for ocular adverse events, according to a large cohort study.

Among over 200,000 men using phosphodiesterase type 5 inhibitors (PDE5Is), the adjusted incidence rate ratio (IRR) for the composite endpoint of serous retinal detachment (SRD), retinal vascular occlusion (RVO), and ischemic optic neuropathy (ION) was 1.85 (95% CI 1.41-2.42), reported Mahyar Etminan, PharmD, MSc, of the University of British Columbia in Vancouver, and colleagues in JAMA Ophthalmology.

When analyzed by individual outcome, the adjusted IRRs were:

  • 2.58 (95% CI 1.55-4.30) for SRD
  • 1.44 (95% CI 0.98-2.12) for RVO
  • 2.02 (95% CI 1.14-3.58) for ION

These ocular adverse events have previously been reported with use of PDE5Is, but mostly in the form of anecdotal studies that produced inexact estimates for these risks. “Results of this study suggest that individuals who regularly use PDE5Is should be cognizant of ocular adverse events associated with these drugs and alert their physicians if they experience any visual deficits,” the authors wrote.

In an accompanying commentary, Brian L. VanderBeek, MD, MPH, MSCE, of the University of Pennsylvania in Philadelphia, and Maureen G. Maguire, PhD, of the JAEB Center for Health Research in Tampa, Florida, noted that “this study also had a weakness that has plagued previous inquiries into the ocular adverse events related to PDE5I use.”

Many of the risk factors for the indications for using PDE5Is — hypertension, diabetes, and coronary artery disease — are also risk factors for SRD, RVO, and ION, they added, and the prevalence of these risk factors in this study was substantially higher among cases versus controls.

When Etminan and colleagues restricted the primary analysis to cases without hypertension, diabetes, or coronary artery disease, the IRR remained high, at 2.12 (95% CI 1.34-3.43).

However, “residual confounding could have occurred owing to a lack of adjustment for other common risk factors between erectile dysfunction and the adverse events,” VanderBeek and Maguire wrote. Furthermore, “residual confounding frequently yields overestimation of the risk ratios.”

While the study’s findings suggest that PDE5I use may be associated with serious ocular adverse events, causality can’t be proved by using only observational data, they concluded. “Future studies that reduce residual confounding may bolster the confidence in conclusions regarding PDE5I use and these adverse events.”

Data for this study came from the PharMetrics Plus database from January 2006 through December 2020. The study cohort included 213,033 users of PDE5Is, including sildenafil (Viagra, Revatio), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra), who did not use any of the drugs in the year before study entry. The nested case-control analysis included 278 cases of SRD, 628 of RVO, and 240 of ION, as well as 4,584 controls. Mean age in both the case and control groups was 64.6 years.

Risk factors were more common in case patients versus controls: hypertension (24.6% vs 8.9%), diabetes (38.1% vs 26.1%), coronary artery disease (36.1% vs 24.0%), and sleep apnea (15.5% vs 10.6%).

An analysis comparing the risk between men taking five or more PDE5I prescriptions compared with those taking fewer than five prescriptions showed a dose-response association with ocular adverse events (IRR 2.90, 95% CI 1.15-3.81 vs IRR 1.74, 95% CI 1.10-6.77).

When analyzed by individual outcome in this analysis, the adjusted IRRs were:

  • 1.90 (95% CI 1.41-2.55) vs 1.73 (95% CI 1.14-2.64) for SRD
  • 2.39 (95% CI 1.38-4.14) vs 3.30 (95% CI 1.48-7.38) for RVO
  • 1.55 (95% CI 1.00-2.40) vs 1.25 (95% CI 0.70-2.21) for ION

Etminan and colleagues acknowledged that they only had data on drug dispensation and not on actual consumption, which was a study limitation.

  • author['full_name']

    Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

Disclosures

This study was funded by the Department of Ophthalmology and Visual Sciences at the University of British Columbia.

Etminan reported no disclosures. A co-author reported financial support from the Novartis Advisory Board and Roche Advisory Board outside the submitted work.

VanderBeek reported receiving consulting fees from EyePoint Pharmaceuticals. Maguire reported no disclosures.

Posted on

Life events that influence estrogen levels may be linked to woman’s dementia risk in later life

Life events that influence estrogen levels may be linked to woman's dementia risk in later life

Life events that influence levels of the female hormone estrogen may be linked to a woman’s risk of developing dementia in later life, according to new research.

The analysis found that some reproductive events – like an early or late start to menstruation, early menopause and hysterectomy – were linked to higher risk of dementia while ever having been pregnant or having had an abortion and later menopause were linked to lower risk.

But childbearing was not one of them, with a similar relationship observed between the number of children and dementia risk in men and women.

Lead author Jessica Gong from The George Institute for Global Health said that although it appeared reproductive events related to changes in hormone levels in women may be involved in dementia risk, the exact relationship was still unknown.

“While the risk of developing dementia increases with age, we don’t yet know whether the higher rates seen in women are simply because they live longer,” explained Ms Gong. “But it’s possible that female-specific reproductive factors may be able to explain some of the sex differences.”

Dementia is fast becoming a global epidemic, currently affecting an estimated 50 million people worldwide. This is projected to triple by 2050 – mainly driven by aging populations. Rates of dementia and associated deaths are both known to be higher in women than men.

Estradiol is the most predominant form of estrogen during reproductive life (from the start of menstruation to menopause) and estriol is the primary estrogen during pregnancy. Use of hormones that originate from outside the body, such as oral contraceptives during reproductive years, and hormone replacement therapy (HRT) in later life can also influence estrogen levels.

To examine these relationships in more detail, George Institute researchers analyzed data on a total of 273,240 women without dementia who were registered with the UK Biobank, a large-scale biomedical database. After adjusting for other factors that could have influenced the results, they found the following were associated with an increased risk of dementia:

  • Early and late first occurrence of menstruation, younger age at first birth, and hysterectomy – specifically hysterectomy without surgical removal of one or both ovaries, or if the hysterectomy took place after ovary removal.

Conversely, the factors associated with a decreased risk were ever having been pregnant, ever having had an abortion, longer reproductive lifespan and later menopause.

“With regard to external hormones, the use oral contraceptive pills was associated with a lower risk of dementia, but our study findings did not support an association between HRT and dementia risk,” Ms Gong said.

The authors proposed that risk variation in women may not be associated with childbearing because a similar pattern was observed between number of children fathered and dementia risk among a similar number men in the same study.

“We found that the higher dementia risk linked to early (natural and artificial) menopause was more pronounced in women of lower socioeconomic status,” she added.

“Social deprivation is likely to be an important determinant of dementia risk as well as other aspects of women’s health.”

With dementia on the rise and in the absence of significant treatment breakthroughs, the focus has been on reducing the risk of developing the disease.

“More research is needed to understand whether these differences are associated with life-long exposure to the body’s own estrogen, and whether external hormone use could influence the risk of developing dementia,” added Ms Gong.

“Our findings may be helpful for identifying high-risk women to participate in future clinical trials to assess potential preventive measures and treatments.”

Source:

Journal reference:

Gong, J., et al. (2022) Reproductive factors and the risk of incident dementia: A cohort study of UK Biobank participants. PLOS Medicine. doi.org/10.1371/journal.pmed.1003955.